Although no objective responses are observed, an interesting trend of longer median time to progression is observed among patients with Kirsten rat sarcoma 2 viral oncogene homolog-mutant non-small cell lung cancer compared to wild-type.
← all excerpts
Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma.
1
—
—